Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.

Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL
Cancer Res. 2013 73 (19): 6013-23

PMID: 23918797 · PMCID: PMC3790862 · DOI:10.1158/0008-5472.CAN-13-1191

MeSH Terms (23)

Animals Antibodies, Monoclonal, Humanized Antineoplastic Agents Breast Neoplasms Cell Proliferation Class I Phosphatidylinositol 3-Kinases Female Humans Immunoblotting Immunoprecipitation Lapatinib Mice Phosphorylation Protein Multimerization Proto-Oncogene Proteins c-akt Quinazolines Receptor, ErbB-2 Receptor, ErbB-3 Signal Transduction Survival Rate Trastuzumab Tumor Cells, Cultured Xenograft Model Antitumor Assays

Connections (2)

This publication is referenced by other Labnodes entities: